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Abstract 
Introduction: All antiretroviral therapies (ARTs) are potentially toxic to the liver. In sub-Saharan Africa, 
the rising incidence of ART induced liver injury has complicated treatment leading to recent revisions 
of Namibian ART guidelines. Unfortunately there have been limited studies to date evaluating ART 
induced liver injury in Namibia to guide further revisions if needed. Objective: Determine the current 
SDWWHUQVDQGJUDGHVRI$/7HOHYDWLRQLQ1DPLELD¶V+,9$,DS. Methods: Retrospective cohort analysis. 
Patterns of alanine amino transferase (ALT) liver enzyme elevation were determined in a cohort of 
ART naïve HIV patients on firstline ART regimen in a referral hospital in Namibia over a 1 year 
treatment period. Patterns of ALT changes at baseline, 3 months and 6 months were analyzed using 
ANOVA and Bonferroni test for pairwise comparisons. Results: Of 79 eligible patients, 72 developed 
significant ALT elevation within 3 months of ART initiation (F (3, 76) = 6.4, p = 0.002, Ș2= 0.193). Four 
4 (5.6%) and 1 (1.38%) patient respectively developed grade 2 and grade 3 ALT elevation by month 
3. There was no significant difference between mean ALT levels at baseline and month 6. A CD4 
count of < 350 cells/mm3; female gender and age over 40 years were the main factors associated with 
moderate or severe ALT elevation. Conclusions: First line ART commonly induce mild self-limiting 
liver enzyme elevation in Namibian HIV patients especially in the first 3 months. Consequently, there 
is a need to monitor ALT levels for at least 3 months after initiation mainly in high risk patients to 
reduce side-effect concerns. This is already happening.  
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Highlights 
x All antiretroviral therapies (ARTs) are potentially toxic to the liver. This is particularly important in 
sub-Saharan Africa where the rising incidence of ART induced liver injury, where the majority of 
WKHZRUOG¶V+9$,'6SDWLHQWVFXUUHQWUHVLde, has complicated HIV treatment leading to recent 
revisions of guidelines  
x Despite these concerns, there have been limited studies evaluating ART induced liver injury in 
these countries, especially Namibia with its high HIV burden. This need to be addressed to guide 
future clinical practice especially with a high female population with HIV in Africa who may have 
different responses to treatment to male HIV patients typically seen in Western countries  
x The majority of patients in this study had developed significant ALT elevation within 3 months of 
ART initiation. There was no significant difference between mean ALT levels at baseline and 
month 6 
x Based on our findings, patients with high risk of hepatocellular damage such as low baseline CD4 
count , of female sex, and > grade 2 ALT elevations, and patients who test positive for HBV/HCV, 
should be monitored for at least 6 months after initiation of NVP and EFV based ART. This is 
already happening in Namibia 
 
1. Introduction 
 
HIV/AIDS has devastated public health in sub-Saharan Africa. This is a concern since this region 
despite being resource constrained hosts over 80% of the ZRUOG¶V HIV patients1. Within Africa, 
UNAIDS ranks Namibia among countries with the highest prevalence of HIV/AIDS among adults aged 
15-49 years (14.3%), with currently over 250,000 people out of a population of 2.3 million in Namibia 
living with the infection2, 3 . Since the rollout of antiretroviral therapy (ART) in Namibia in 2003, over 
104, 531 (80%) HIV/AIDS patients have been initiated on treatment3,4. Recently the test and treat 
policy has led to a considerable scale up of patients on first-line ART regimens. Unfortunately scale-
up of ART exposes some patients to adverse drug reactions (ADRs)5 - 10  with liver damage 
characterized by an elevation of alanine aminotransferase (ALT) being the most common11 - 14. 
Pharmacovigilance reports in Namibia have shown an increasing incidence in adverse effects that 
parallel the scale-up of ART15, particularly with stratification by CD4 count15 ± 20, female sex12, 20 and 
the use of non-nucleoside reverse transcriptase inhibitors (NNRTIs)19,20,22-25. 
 
The high number of female patients initiating ART15, 26 is an important risk factor for ART induced 
adverse effects including renal impairment - with hormonal differences playing a part15, 21. Despite 
these risk factors, ART initiation policies in Namibia has evolved based on increasing CD4 thresholds: 
250 cells/mm3 (2003); 350 cells/mm3 (2010); 500 cells/mm3 (2014) and currently to test and treat 27-29. 
Unfortunately to date, there have been limited studies evaluating the grades and risk factors for ART 
induced hepatotoxicity among the Namibia HIV/AIDS population. This is particularly important as the 
risk for ART induced hepatotoxicity among HIV patients in Namibia may be heightened by the high 
rates of tuberculosis (TB)30, high alcohol consumption per capita (12.28 litres per person per year)31 
and the use of efavirenz and/or nevirapine based therapies as first line ART treatment in line with 
recommendations20,22-25,27 - 29.  TB coinfection and co-medication is an important risk factor for 
hepatotoxicity32-33. Liver damage characterized by elevation in liver transaminases through alanine 
amino transferase (ALT) is the most reliable marker for hepatocellular toxicity 11, 20, 34-36; however, it¶s 
measurement among patients on firstline ART in Namibia is currently unknown. The routine 
monitoring of ALT in Namibia is complicated by limited human resource capacity, which may 
negatively impact on treatment outcomes in some patients. 
 
Consequently, the aim of this paper was to determine the current patterns and grades of ALT 
elevation LQ1DPLELD¶V+,9$,'6SRSXODWLRQ to provide future guidance to the authorities in Namibia 
and other African countries with similar profiles of patients with HIV. This is because ADRs negatively 
impact on treatment adherence16, health related costs, and the social-psychological wellbeing of 
patients37 as well as patient outcomes including their quality of life 8, 38-42.  Increased morbidity and 
mortality related to ADRs is the main reason for revision and switching ART treatment as seen in the 
HIV guidelines in the Namibia8-9, 27 - 29, 43. The use of AZT based regimens from 2003 to 20010 was 
associated with anemia, and stavudine (d4T) based regimens from 2010 to 2015 was associated with 
peripheral neuropathy27-29. The currently preferred Tenofovir-based regimens15 have been associated 
with renal insufficiency and bone dimineralization15, 20, 43. Despite these risk factors for liver damage 
among the Namibian population, evidence on patterns and prevalence of liver toxicity remains limited.  
 
2. Methods 
 
2.1 Study subjects 
The study adopted a retrospective cohort analysis of grades and risk factors for ALT elevation among 
patients on firstline ART regimens. The study population consisted of clinical and laboratory records 
of patients initiated on first-line ART at Katutura Intermediate Hospital (KIH). This is a teaching referral 
hospital referral hospital in Windhoek; the capital city of Namibia, and cares for over 5800 patients on 
active ART from across the Khomas region and Namibia.   
 
Retrospective data was collected over a 12 month period between 1st January 2013 and 1st January 
2014.  The study included records of all adult HIV/AIDS patients (>= 18 years) who completed at least 
12 months of treatment of first line ART regimen.  
 
The first line regimens in this study included tenofovir/lamivudine/nevirapine (TDF/3TC/NVP) or 
tenofovir/lamivudine/efavirenz (TDF/3TC/EFV) combinations. For consistency and reliability, only 
records on ALT levels that had been provided by the National Institute of Pathology (NIP) laboratory 
at KIH were included. All the serum levels of ALT of records included in this study were determined by 
Architect ci8200 Dxc analyzer (Abbot Diagnostics) as per the International Federation Clinical 
Chemistry protocol (IFCC). Patients with severe ALT elevation at baseline and/or with missing 
laboratory records on ALT levels at 3 months and or 6 months were excluded from the study.   
 
Out of the 123 patients who had the first line ART at KIH between January 2013 and 31 January 
2014, 44 patients were excluded as their records did not have ALT measurements at month 3 or 
month 6. Consequently, a total of 79 patient records that met the eligibility criteria were included in the 
study. 
 
2.2 Procedure 
Laboratory data on the liver enzyme (AST) and (AST) profiles of ART naïve patients were collected 
using quantitative methods over a 12 month period and five time points - baseline and months 3, 6, 9 
and 12 of treatment. 'DWDIURPWKHSDWLHQWV¶UHFRUGVZHUHabstracted by the principal researcher 
(PAM) from patient ART treatment records over a 3 months study period - May 2014 to August 2014 
using a pre-tested abstraction tool (Appendix A). Data abstracted includes demographic, clinical and 
laboratory data at baseline, 3 and 6 months. Data collection tools were designed to exclude patient 
identifiable data including patient names.   
 
The main outcome variable was the grades and risk factors for ALT elevation at 3 months and 6 
months of ART treatment.  Data was double entered into Epidata® (version 3.1) entry software for 
management and exported to SPSS® (version 21) software for quantitative analysis. The grades of 
ALT elevation were determined using descriptive statistics such as frequencies (%), mean(X) and 
standard deviation (SD).  The risk factors and patterns of ALT elevation were determined using a chi-
square test (F2) for categorical variables and student t-test and/or ANOVA test for continuous 
variables. The Bonferroni pair-wise Post-hock test was used to compare the mean ALT levels at 
baseline with months 3 and month 6 post ART initiation. The significance level for a 95% confidence 
interval was set at a p value < 0.05. Missing data were excluded in the analysis.  
 
2.3 Criteria for grading ALT elevation  
The grades of ALT elevations were determined using the WHO toxicity scale based on the upper 
limits of normal (ULN) ALT levels 35, that is  normal or grade 1 (<2.5xULN); mild - moderate elevation 
or grade 2 (2.5-5 x ULN); severe elevation or grade 3 (>5 x ULN) or grade 4 (> 10 x ULN). The normal 
limits of ALT levels were considered to be 0 ± 40 IU/L34,44,46. 
 
2.4 Ethics 
The study was approved by the University of Namibia (UNAM), the Ministry of Health and Social 
Services (MoHSS) and Namibia Institute of Pathology (NIP) research and ethics committees. The 
need for informed consent was waved by the research committee as the study was based on patient 
records with no direct contact with patients. Patient codes or serial numbers were used instead of 
patient identifiers such as names to delink the patients from the data collected. All collected data was 
safely stored. 
 
3. Results 
 
A total of 79 patient records that met the eligibility criteria were included in the study. 44 patients were 
excluded as their records did not have ALT measurements at month 3 or month 6. 
 
3.1 Baseline demographic and clinical characteristics  
The majority of the study subjects were female (n = 51 (65%), p = 0.01) aged between 30 - 40 years 
(n=41 (52%), p = 0.000); were not married (76%), (p =0.000) and did not consume alcohol 
(n=61(78%); p = 0.149). The majority of the subjects were initiated on a NVP based regimen (n=53 
(82%), p = 0.000); were WHO clinical state 1 or 2 (n=59 (85%), p = 0.000) with a CD4 count of < 350 
cells/mm3 (n=69 (89.6%), p = 0.000); did not have TB co-infection (n=72 (98%), p = 0.000) and had 
an ART adherence level of > 90% (n=64(92%), p = 0.000)   (Table 1).  
 
Table 1:  Baseline demographic and clinical characteristics of the study subjects (n=79) 
 
Characteristic Total (%) F2 P-value*   
Sex                                     
Female      
Male 
 
 
51(65) 
28(35) 
 
 
6.696 
 
 
0.010 
Age category 
20-30 years 
31-40 years 
41-50years 
>50 years 
 
11(14) 
41(52) 
20(25) 
7(9) 
 
 
 
 
36.359 
 
 
 
 
0.000 
ART Regimen 
TDF/3TC/EFV 
TDF/3TC/NVP 
 
 
14(18) 
65(82) 
 
 
 
21.525 
 
 
 
0.000 
Alcohol consumption 
Yes 
No  
 
17(22) 
62(78) 
 
 
2.082 
 
 
0.149 
Clinical stage        
Stage 1 
Stage 2 
Stage 3 
Stage 4  
 
45(63) 
14(22) 
18(11) 
3(4) 
 
 
 
 
30.490 
 
 
 
 
0.000 
CD4 categories  
<250cells/mm3 
251-350cells/mm3 
351-500cells/mm3 
>500cells/mm3 
 
40(52) 
29(38) 
5(6.5) 
3(3.5) 
 
 
 
 
25.224 
 
 
 
 
0.000 
Co-infection 1st visit 
TB 
No signs 
 
7(2) 
72(98) 
 
 
24.352 
 
 
0.000 
Adherence to ART 
>90%  
70 - 87%  
< 90% 
 
64(92) 
6(5) 
5(3) 
 
 
 
11.109 
 
 
 
0.004 
Medicines on 1st visit 
Co-trimoxazole therapy 
TB treatment & CTX 
 
72(98) 
7(2) 
 
 
24.352 
 
 
0.000 
    
* Pearson chi-square test 
 
3.2 Patterns of Alanine amino transaminase (ALT) elevation among study subjects  
The analysis of variance (ANOVA) of the mean ALT levels among study subjects at baseline, month 3 
and month 6 after the initiation of first line, ART was statistically significant ( F (3, 76) = 6.4, p = 0.002, 
Ș2= 0.193) (Table 2).  
 
  
Table 2:  Patterns of biomarkers for HAART efficacy and toxicity among the subjects 
 
Characteristic Mean ± SD F2 F Ș2 P-value 
ALT (IU/L) 
baseline 
 month 3 
 month 6 
 
29.85±23.977 
50.62±41.035 
44.12±35.461 
 
 
 
2.810 
 
 
 
6.940 
 
 
 
0.193 
 
 
 
0.002 
CD4 (cells/mm3) 
 baseline 
 month 2 
 
265.00±141.033 
433.82±181.226 
 
 
0.000 
 
 
42.761 
 
 
0.466 
 
 
0.000 
Haemoglobin  
 baseline 
month 6 
 month 9 
(g/dL) 
12.026±2.2339 
13.617±1.8127 
13.561±1.7188 
 
 
 
2.970 
 
 
 
9.975 
 
 
 
0.487 
 
 
 
0.001 
Serum creatinine  
baseline 
month 3 
month 6 
month 9  
(mmol/L) 
73.82±13.553 
69.27±13.854 
71.05±18.269 
73.09±15.826 
 
 
 
 
26.869 
 
 
 
 
2.969 
 
 
 
 
0.319 
 
 
 
 
0.580 
Body weight  (kg) 
baseline 
month 1 
month  2 
month 3 
month 4 
month 5 
 
63.552±13.5028 
63.772±13.5840 
64.400±13.9013 
65.534±13.7929 
66.085±13.3924 
65.628±13.7351 
 
 
 
 
 
 
109.262 
 
 
 
 
 
 
3.330 
 
 
 
 
 
 
0.217 
 
 
 
 
 
 
0.010 
NB: ALT: Alanine amino transferase 
 
This suggests evidence to conclude there is a difference between the ALT levels by initiation and 
duration of ART treatment with an appreciable effect size (Ș2 > 0.14).  A post hoc comparison to 
evaluate pair wise difference between the mean ALT levels at baseline, month 3 and month 6, using 
the Bonferroni test to control for type I error, showed a significant increase in the mean ALT levels 
between baseline and month three (p = 0.001) as well as baseline and month six after the initiation of 
ART (p = 0.02). The ALT levels were higher at month three and month 6 compared to baseline (Table 
3).  
 
Table 3:  Pair wise comparison of ALT levels at base line, month 3 and month 6 
 
Characteristic  Mean difference  P *-value 
 
ALT month 0 
 
ALT month 3 
ALT month 6 
 
-20.767 
-14.267 
 
0.001 
0.020 
 
ALT month 3 
 
ALT month 0 
ALT month 6 
 
20.767 
6.500 
 
0.001 
0.500 
* Bonferroni Post Hoc Test 
 
3.3 Prevalence of grades of ALT elevation among the study subjects 
Out of the 79 patients at baseline, 77(97.5%) and 2 (2.5%) had grade 1 and grade 2 ALT elevation 
respectively. At 3 months post ART initiation, out of the 72 (91.1%) patients who had their ALT results 
recorded; 67 (93.1%) had grade 1, 4(5.6%) had grade 2 and 1(1.34%) had grade 3 ALT elevation. At 
6 months post ART initiation, out of the 66 (83.5%) patients who had their ALT determined; 62 
(93.9%) had grade 1 and 4 (6.1%) had grade 2 ALT elevation. Out of the five 5(6.9%) patients that 
developed grade 2 or 3 ALT elevation by month 3 post ART initiation, the majority were taking a NVP 
based regimen, had a baseline CD4 count < 350 cells/mm3, were of the female gender, were aged 
more than 40 years and were classified by WHO HIV clinical stage I (Table 4). The study also found 
that the initiation of ART significantly increased mean CD4 counts, level of hemoglobin and the 
SDWLHQW¶VERG\weight. The first ART regimen was associated with an increase in the mean serum 
creatinine levels also increased after the initiation of ART (Table 4; Figure 3).   
 
Table 4:  Factors associated with elevation of ALT at month 3 (n = 5) 
 
Characteristic  # of patients by ALT elevation Total (%) P -value 
Grade 2 Grade 3 
CD4 counts 
< 250 cells/mm3  
251 - 350 cells/mm3  
 
2  
2  
 
- 
1  
 
2(40) 
3(60) 
 
 
0.361 
ART regimen 
TDF/3TC/EFV 
TDF/3TC/NVP 
 
1 
3 
 
 
1 
 
1 (20) 
4(80) 
 
 
0.576 
Sex 
Male 
Female 
 
1 
3 
 
 
1 
 
1 (20) 
4(80) 
 
 
0.576 
Age of patient 
41 ± 50 years 
> 50 years 
 
3 
 
 
 
1 
 
3(75) 
1(25) 
 
 
0.046 
Clinical stage  
Stage 1 
Stage 3 
 
3 
1 
 
1 
- 
 
4(80) 
1(20) 
 
 
0.576 
Alcohol intake 
Yes 
No 
 
 
1 
3 
 
 
1 
 
1 (20) 
4(80) 
 
 
0.576 
TB coinfection 
Yes 
No 
 
 
1 
3 
 
 
1 
 
1 (20) 
4(80) 
 
 
0.576 
 
 
There were a higher number of female patients with normal ± grade 1 and 2 - as well as with severe 
liver enzyme elevation (Figure 1).  The elevation in ALT at 3 months was associated with the baseline 
ALT levels (Figure 2) and CD4 count. The elevation in ALT was negatively correlated with the 
baseline CD4 counts (Figure 3). 
 
  
Figure 1: Grades of ALT elevations by sex of patient after 3 months of ART initiation 
 
 
 
Figure 2: Grades of ALT elevations by sex of patient after 3 months of ART initiation 
 
 
  
Figure 3: Grades of ALT elevations by CD4 counts after 3 months of ART initiation 
 
 
4. Discussion 
 
We found that first line ART regimens were associated with significant elevation of ALT from baseline 
to 3 months, with ALT levels normalized by the months 6 of therapy. These findings concur with 
studies by Lucien et al., Uberti-Foppa, Teklay et al. and De Maat et al. who found an increased ALT 
elevation following ART with in the first month of treatment7,11, 22,35. Studies have associated NNRTI 
based regimens with early onset of ALT elevations16, 39, 46.  However our findings differ from studies by 
Lucien et al., Splenger et al., and Bossi et al., regarding the patterns of the ALT elevation, which 
showed long term elevation of ALT with duration of treatment6,11,17. These studies, unlike our study, 
evaluated regimens with thymidine analogues (AZT or d4T) that have been associated with long term 
mitochondrial toxicity related liver damage39. This is unlike this study where adenosine analogue 
(TDF) based regimens were used, and have been referred to as safe to the liver8.  TDF regimens 
were used as currently the recommended first line ART regimen in Namibia is TDF/lamivudine 
(3TC)/Nevirapine (NVP) or Efavirenz (EFV)29. 
 
We also found a low incidence of moderate or grade 2 ALT elevation in 4 patients (5.6%) and severe 
or grade 3 elevation in only 1 patient (1.39%) who had ALT elevation at 3 months of ART initiation.  
Studies in Ethiopia, Zambia, and Palmon et al. also showed mild liver enzyme elevation in patients 
initiated on TDF based regimens7,9,23.  However these findings differ from those of Martinez et al, 
Sulkowsky, Verucchi et al, Tetrault et al and Manfredi et al, whose incidence of severe ALT elevation 
were 8% and 17.5% for EFV and NVP respectively18,24,25,45, 47 . A study in Cameroon by Lucien et al. 
found 22.67% (34/150) presented with transaminitis with respect to ALT11, with a study undertaken in 
the US among 352 subjects found 81 subjects developed elevated liver enzymes over the 96 week 
follow up period19. In this US study, the cumulative incidence of liver enzyme elevation was 5.7% at 
month 1, 9.2% at month 2, 11.5% at month 3, 17.3% at month 6 and 19% at month 919. A slightly 
higher rate of efavirenz associated hepatotoxicity (12.5%) was observed in a prospective cohort study 
by Maggiolo et al. and Shubber et al.12,14. Whilst not statistically significant, our study found that grade 
2 (moderate) and or grade 3 (severe) ALT enzyme elevations were associated with the use of NVP 
based regimens, initiation of ART in patients in the WHO Clinical Stage I, and older than 40 years. 
This was similar to the findings of Lucien et al, Spengler et al, and Hawkins et al., where ALT 
elevations were greater in patients > 40 years, females and having a CD4 count of less than 350 
cells6,11,48. Previous studies have associated liver damage with the NVP based regimens20,22-25 and 
the female sex16. The higher incidence may parallel the higher enrollment of female patients on ART 
programmes in African countries15, 26 ± 29. Contrary to findings of this study (Figure 2), liver toxicity of 
NVP base ART regimens has been associated with higher CD4 counts of > 250 in female patients 
and > 400 cellm3 in male patients46.   This may be because these studies have traditionally been 
undertaken among Western countries with different patient populations and pharmacogenomics26. 
 
We accept that the main limitation of this study is the retrospective design ± with a number of patients 
missing complete records on their ALT measurements; consequently, they were excluded. A 
prospective randomized clinical trial is ideal but may not be realistic in settings with limited resources. 
This is consistent with the fact that most studies in the African setting on ART induced liver damage 
have used retrospective data5, 11. However, we controlled for bias with paired samples in our study 
design. In addition, we were also aware that this study was undertaken in only one centre in Namibia. 
Never-the-less, we believe in view of the fact that we had 79 patients with paired ALT measurements 
(3x79 tests) for 3 months, and ANOVA analysis indicated significant differences at different treatment 
time points, that our findings are robust and would not have been different if we had included 
additional patients or additional centers in Namibia. 
 
5. Conclusion 
First line ART regimens commonly induce mild self-limiting liver enzyme elevation in Namibian HIV 
patients especially in the first 3 months of therapy. However, the incidence of moderate to severe first 
line ART induced liver toxicity is low. Patients of the female gender, aged over 40 years with a CD4 
count of less than < 350 and the use of NVP based regimens may be at greater risk of developing 
moderate to severe liver damage. Consequently, there is a need to monitor ALT levels for at least the 
first three months after initiation of therapy mainly in female patients, patients with grade > 2 ALT 
elevations at baseline and patients with low CD4 counts, as well as patients on co-medication for 
tuberculosis.  
 
In view of this, a different approach to monitoring liver toxicity may be warranted and should be 
incorporated in guidelines to monitor ART toxicity. This approach should be based on clinical signs 
and symptoms for hepatocellular injury such as jaundice as well as asymptomatic elevations in ALT at 
baseline and three months for all patients initiated on ART. We believe based on our findings that 
patients with high risk of hepatocellular damage such as low baseline CD4 count , of female sex, and 
> grade 2 ALT elevations, and patients who test positive for HBV/HCV, should be monitored for at 
least 6 months after initiation of NVP and EFV based antiretroviral therapy. The Ministry of Health in 
Namibia has started to implement these practices, and we will be monitoring the results in future 
research projects. These findings may also be of interest to other African countries. 
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Appendix A: data abstraction tool 
 
DATA ENTRY TOOL 
First-line antiretroviral therapy induced liver enzyme elevation in a cohort of 
HIV/AIDS patients in Namibia: findings and implications 
 
100. Serial number      
Patient information 
101. Patient ID 
102. Gender                       (1)        male  (2)        female 
103. Date of birth 
104. Confirmed HIV status      (1)        yes       (2)        no 
105. Date ART started  
106. Regime          (1)        TDF/3TC/EFV            (2)        TDF/3TC/NVP (3) 
other ________________ 
107. Weight (kg) 
108. Clinical stage (1)        I    (2)        II          (3)        III   (4)        IV     
(5)        not stated 
109. CD4 count (cells/uL) 
110. Marital status  (1)        single   (2)        married (3)        divorced (4) 
other_________________ 
111. Alcohol intake (1)         yes  (2)         no 
 
 
 
  
ART card 
112. 
Date  
113.Weight 
(kg) 
114.Clinical 
stage of HIV 
115.Co-
infections 
116.New 
problems (co-
morbidities) 
117. 
Adherence 
118. Other 
medicines 
prescribed 
       
       
       
       
       
       
       
       
       
       
 
  
Laboratory results 
Parameter  Base
line 
Mo
nth 
1 
Mo
nth 
2 
Mo
nth 
3 
Mo
nth 
4 
Mo
nth 
5 
Mo
nth 
6 
Mo
nth 
7 
Mo
nth 
8 
Mo
nth 
9 
Mo
nth 
10 
Mo
nth 
11 
Mo
nth 
12 
119. 
Haemoglobin(
g/dl) 
             
120.Creatinine 
clearance(umo
l/L) 
             
121. ALT(u/L)              
122. Viral load              
123. CD4 
count 
(cells/uL) 
             
124. 
Hematocrit 
(%) 
             
125. 
Neutrophils(x
109/L) 
             
126.Lymphoc
ytes(x109/L) 
             
127. Total 
WBC(x109/L) 
             
128.Platelets 
(x109/L) 
             
 
